The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: Results from the FREEDOM extension

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 11, 2013, Pages 4483-4492

  Bone, Henry G ^a   Chapurlat, Roland ^b   Brandi, Maria Luisa ^c   Brown, Jacques P ^d,e   Czerwiński, Edward ^f   Krieg, Marc Antoine ^g   Mellström, Dan ^h   Radominski, Sebastião C ⁱ   Reginster, Jean Yves ^j   Resch, Heinrich ^k   Román Ivorra, Jose A ^l   Roux, Christian ^m   Vittinghoff, Eric ⁿ   Daizadeh, Nadia S ^o   Wang, Andrea ^o   Bradley, Michelle N ^o   Franchimont, Nathalie ^o   Geller, Michelle L ^o   Wagman, Rachel B ^o   Cummings, Steven R ⁿ   Papapoulos, Socrates ^p   more..

^a Michigan Bone and Mineral Clinic   (United States)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITY OF FLORENCE   (Italy)

^d LAVAL UNIVERSITY   (Canada)

^e UNIVERSITÉ LAVAL   (Canada)

^f Krakow Medical Center   (Poland)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^j UNIVERSITY OF LIÈGE   (Belgium)

^k St Vincent Hospital   (Austria)

^l HOSPITAL UNIVERSITARIO LA FE   (Spain)

^m UNIVERSITÉ PARIS DESCARTES   (France)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o AMGEN INC   (United States)

^p LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; DENOSUMAB; PLACEBO; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BONE DENSITY; BONE TURNOVER; BREAST CANCER; CELLULITIS; COLON CANCER; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; ERYSIPELAS; FEMALE; FEMUR FRACTURE; FRAGILITY FRACTURE; HIP; HUMAN; HYPOCALCEMIA; INFECTION; INTERNATIONAL COOPERATION; JAW OSTEONECROSIS; LONG TERM CARE; LUMBAR SPINE; LUNG CANCER; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; OPEN STUDY; OSTEOSYNTHESIS; OUTCOME ASSESSMENT; PANCREATITIS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINE FRACTURE; TREATMENT DURATION;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY; CROSS-OVER STUDIES; FEMALE; FRACTURES, BONE; HUMANS; INCIDENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS; RANK LIGAND; RISK FACTORS; TIME;

EID: 84887456516     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1597     Document Type: Article

References (18)

1. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol. 2005; 5: 618-625.
2. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423: 337-342.
3. Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367: 2010-2018.
4. Bone Health and Osteoporosis. A Report of the Surgeon General. Bethesda, MD: US Department of Health and Human Services.
5. Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility.NEngl J Med. 2006;354:2250- 2261.
6. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo- controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19: 1059-1066.
7. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354: 821-831.
8. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361: 756-765.
9. McClung MR, Lewiecki EM, Geller ML, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int. 2013;24: 227-235.
10. Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27: 694-701.
11. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8: 1137-1148.
12. Thomas D, Carriere P, Jacobs I. Safety of denosumab in giant-cell tumour of bone. Lancet Oncol. 2010;11:815.
13. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010; 25: 2267-2294.
14. Vittinghoff E, McCulloch CE, Woo C, Cummings SR. Estimating long-term effects of treatment from placebo-controlled trials with an extension period, using virtual twins. Stat Med. 2010;29:1127- 1136.
15. Austin M, Yang YC, Vittinghoff E, et al. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res. 2012;27: 687-693.
16. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48: 677-692.
17. Seeman E, Delmas PD, Hanley DA, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010;25: 1886-1894.
18. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350: 1189-1199.